Heart valve study: which blood thinner prevents clots best after TAVR?
NCT ID NCT05493657
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study compares aspirin and clopidogrel to prevent leaflet thrombosis (blood clots on the valve) in 254 people who had a transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. After 4 weeks of both drugs, participants take either aspirin or clopidogrel alone for 6 months. The main goal is to see which drug reduces valve clots better, checked by CT scan at 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin and clopidogrel
What this could lead to
If successful, this could identify the better single antiplatelet drug to prevent dangerous blood clots on the new heart valve after TAVR, improving long-term safety.
What could go wrong
This is a relatively small, early-phase trial (254 people) comparing two common drugs, so the difference may be small or not apply to all patients. The study only follows patients for 6 months, so longer-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••